NCT03489551View on ClinicalTrials.gov

Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions
Stem Cell Transplant ComplicationsDelirium
Interventions
DRUG

Haldol

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

Michelle Weckmann

OTHER

NCT03489551 - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients | Biotech Hunter | Biotech Hunter